Symposia: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
Oral and Poster Abstracts
Oral
Research, Lymphoid Leukemias, ALL, Hodgkin lymphoma, Translational Research, CLL, Lymphomas, non-Hodgkin lymphoma, Non-Biological therapies, LGL, B Cell lymphoma, Plasma Cell Disorders, genomics, bioinformatics, Chemotherapy, Combination therapy, T Cell lymphoma, drug development, Diseases, indolent lymphoma, aggressive lymphoma, Therapies, immunology, therapy sequence, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures, molecular biology, Study Population, Human, pathogenesis, omics technologies
288-290
(Ernest N. Morial Convention Center)
Moderators:
Jennifer Kimberly Lue, MD, Memorial Sloan Kettering Cancer Center
and
Patrizia Mondello, MD, PhD, MSc, Memorial Sloan Kettering Cancer Center
Disclosures:
Lue: Epizyme: Consultancy; TG Therapeutics: Consultancy.
12:00 PM
Yang Y Ding, MD1,2, Joseph Patrick Loftus, BS1*, Benjamin Mathier, BS1*, Wenbao Yu, PhD1,3*, David Hottman Allen, PhD1*, Bing He, PhD4*, Catherine D Falkenstein, BS1*, Sarah K Tasian, MD1,2 and Kai Tan, PhD2,3,5
1Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA
2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
3Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA
4Pennsylvania State University College of Medicine, Hershey, PA
5Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
12:15 PM
Xinting Hu1, Ya Zhang, MD2,3*, Hua Wang, MM2*, Yang Han, MD2*, Zheng Tian, MM3*, Xin Zhang, MM3*, Liyan Lu2* and Xin Wang2,3
1Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
2Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
3Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China
12:30 PM
Brian Estrella, PhD1*, Manuel A Pazos II, MS2*, Edd C Ricker, PhD2, Yun Kyoung Ryu, MD, PhD2, Ted B. Piorczynski, Ph.D3*, Yuxuan Liu, Ph.D.4*, Seda Tolu, MD3 and Jennifer E. Amengual, MD5
1Herbert Irving Comprehensive Cancer Center, Division of Hematology-Oncology, Columbia University, New York, NJ
2Herbert Irving Comprehensive Cancer Center, Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY
3Division of Hematology Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY
4Department of Pediatrics, Hematology, Oncology, and Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, CA
5Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York
12:45 PM
Jiye Liu, PhD1*, Lijie Xing, MD1,2*, Teru Hideshima, MD, PhD1, Keiji Kurata3*, Mehmet K. Samur, PhD3,4, Eugenio Morelli, MD5, Kenneth Wen6*, Nikhil C Munshi, MD, PhD7 and Kenneth C. Anderson, MD8
1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Department of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
3Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
4Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
6Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
7The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
8LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
1:00 PM
Shanshan Suo, MD1,2*, Dandan Zhao, MD1*, Fenglin Li2*, Sonia Rodriguez, PhD1*, Junjing Qiao, MD, PhD1*, Chen Liang, MD1*, Le Xuan Truong Nguyen, PhD1*, Dinh Hoa Hoang, BS1*, Fang Chen1*, Ivan Rodriguez1*, Lucy Ghoda, PhD1*, Tinisha McDonald1*, Ling Li, PhD1, Nadia Carlesso, MD PhD1, Bin Zhang, PhD1, Guido Marcucci, MD1 and Jie Jin, M.D., Ph.D.2
1Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope, Duarte, CA
2Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
1:15 PM
Manuel Quadri, PhD student1*, Claudia Saitta, PhD1*, Sonia Palamini, Graduated student1*, Chiara Palmi, PhD2*, Jia-Wey Tu3*, Sanil Bhatia, PhD3*, Arndt Borkhardt, MD3, Andrea Biondi, MD1, Giovanni Cazzaniga, PhD4,5* and Grazia Fazio, PhD6*
1Tettamanti Research Center, Dept. Pediatrics, University of Milano-Bicocca, Fondazione MBBM/San Gerardo Hospital, Monza, Italy
2Tettamanti Research Center, Pediatrics, Department of Medicine, University of Milano-Bicocca, Monza, Italy
3Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
4Medical Genetics, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
5Tettamanti Research Center, Pediatrics, University of Milano-Bicocca / Fondazione Tettamanti, Monza, Italy
6Tettamanti Research Center, Dept. Pediatrics, Clinica Pediatrica Univ. Milano Bicocca Ospedale San Gerardo, Monza, MB, Italy
*signifies non-member of ASH
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.